sebi meeting

-


 The SEBI Board Meeting held today, September 30, 2024, had several key issues on the agenda. One of the main topics discussed was tightening regulations for Futures & Options (F&O) trading, aimed at curbing speculative trading, which has led to significant losses for retail investors. Potential measures include restricting multiple contract expiries and monitoring position limits more closely.


Another major item was the introduction of a new asset class, designed to bridge the gap between mutual funds and portfolio management services, primarily catering to high-net-worth individuals. Additionally, SEBI's "MF Lite" regulations, which aim to simplify compliance for passive mutual funds, were also discussed, with a goal to make it easier for retail investors to access these funds.


This meeting also took place against the backdrop of ongoing controversy surrounding SEBI Chairperson Madhabi Puri Buch, who has faced allegations related to conflict of interest, though these issues were not officially on the agenda.

Comments

Post a Comment

Popular posts from this blog

DeAndre Hopkins American american football wide receiver

-
Image
  DeAndre Hopkins is an American football wide receiver currently playing for the Tennessee Titans in the NFL. Known for his exceptional catching ability, precise route running, and strong hands, Hopkins has consistently been one of the league's top receivers. He was born on June 6, 1992, in Clemson, South Carolina, and played college football at Clemson University before being selected by the Houston Texans in the first round of the 2013 NFL Draft. Hopkins played for the Texans from 2013 to 2019, establishing himself as one of the most reliable and productive receivers in the NFL. In 2020, he was traded to the Arizona Cardinals, where he continued to perform at a high level before signing with the Tennessee Titans in 2023. Throughout his career, Hopkins has earned multiple Pro Bowl selections and All-Pro honors. Known for his nickname "Nuk," he has made numerous highlight-reel catches and is regarded as one of the best wide receivers of his generation. Pete Prisco's ...
Read more

Microsoft’s Majorana 1 chip carves new path for quantum computing

-
 Microsoft’s Majorana 1 chip carves new path for quantum computing Microsoft has recently unveiled the Majorana 1 chip, a groundbreaking advancement in quantum computing. This chip is notable for being the first to utilize a Topological Core architecture, which is designed to enable quantum computers to solve complex industrial-scale problems much faster than traditional systems.  Key Features of Majorana 1 - Topoconductor Material: The Majorana 1 chip leverages a new type of material known as a topoconductor, which allows for the observation and control of Majorana particles. This capability is crucial for creating more reliable and scalable qubits, the fundamental units of quantum computing[1][2][3]. - Scalability: Microsoft claims that this architecture can potentially fit up to one million qubits on a single chip, dramatically increasing computational power and efficiency. This level of scalability is essential for tackling significant challenges, such as breaking down mic...
Read more

eli lilly weight loss drug india

-
Image
 Eli Lilly has launched its weight-loss and type 2 diabetes medication, Mounjaro (tirzepatide), in India following approval from the Central Drugs Standard Control Organisation. This once-weekly injectable drug is available in single-dose vials, with the 2.5 mg vial priced at ₹3,500 and the 5 mg vial at ₹4,375. Mounjaro functions by activating hormone receptors that regulate blood sugar levels and appetite, aiding in weight management.  However, potential side effects include gastrointestinal issues, pancreatitis, hypoglycemia, and gallbladder problems. Individuals with specific health conditions should consult a doctor before use.  The introduction of Mounjaro is expected to intensify competition in India's obesity treatment market. Novo Nordisk plans to launch its weight-loss drug, Wegovy (semaglutide), by 2026 as its active ingredient is set to go off-patent in India. Additionally, Indian pharmaceutical companies like Sun Pharmaceutical, Biocon, Zydus Lifesciences, C...
Read more